Evaluation of the efficacy of bevacizumab in recurrence metastatic ovarian cancer as a second-line and beyond. Tuj-hlth [Internet]. 2022 Mar. 29 [cited 2026 Nov. 3];44(1):49-57. Available from: https://journal.latakia-univ.edu.sy/index.php/hlthscnc/article/view/12000